Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TRI

Inoviv Launches NeuroKey-3tm, A Quantitative Multiplexed IP-MS Assay to Measure Key Low-Level Markers in Neurodegeneration

LONDON, March 1, 2024 /PRNewswire/ -- Biomarker pioneer, Inoviv, announces the launch of its proprietary NeuroKey-3tm assay, an end-to-end service offering to measure key low-level markers in neurodegeneration in human plasma. The launch of NeuroKey-3tm signifies an important milestone in Inoviv's mission to generate novel molecular insights that transform drug development and healthcare globally. Inoviv will unveil NeuroKey-3tm at AD/PD 2024 on March 5, 2024.

NeuroKey-3tm is the world's first commercially available disease-targeted assay providing absolute quantification from plasma of a unique set of proteins linked to Alzheimer's Disease and Dementia. The comprehensive assay and end-to-end service delivers highly robust and reproducible data to quantify low-level analytes and provides clinical researchers with a full biomarker report containing statistical analysis, graphical data representations, correlation matrices, and quantitative values.

"NeuroKey-3 significantly accelerates clinical trial timelines and offers neurological drug developers a game-changing biomarker strategy that can measure proteins which pharmaceutical companies care about, at the precision needed to enable decision-making and FDA submissions," said Inoviv CEO & co-founder Michael Dove. "NeuroKey-3 provides highly accurate and fully quantitative insights into proteins linked to neurodegeneration and can be adapted to provide definitive data into post-translational modifications, other proteins, lipids, and metabolites."

For more information about NeuroKey-3tm, find us at:

About Inoviv

Our mission is to generate novel molecular insights that transform drug development and healthcare globally. We work with leading pharma and biotech companies to deliver robust and quantitative biomarker analysis to accelerate the development of life-changing treatments.

We are setting the standard for targeted proteomics. Whether you want to discover treatment-responsive biomarkers, create a custom panel, scale up and validate your own assay for clinical studies, or take advantage of our pre-validated panels, we're your trusted proteomics partners. https://www.inoviv.com/


These press releases may also interest you

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

News published on and distributed by: